BNFC June 2018 update
This update contains 5 significant changes, 4 new preparations and 3 dose changes.
Asthma, chronic: updated guidance on management.
Immunoglobulins: updated guidance for Varicella-zoster immunoglobulin.
Quinine: clarification of parenteral dose for the treatment of malaria [dose reduction necessary if parenteral treatment is required for more than 48 hours].
Vaccines: updated guidance for Hepatitis A Vaccine.Vaccines for travel: updated guidance on Hepatitis A.
Dose Changes: Co-codamol [doses for children aged 12 to 15 years].
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide [age-range extension].
Raltegravir [dose for oral suspension—new dose for neonates and update to dose for child with body-weight 3kg; update to directions for administration for oral suspension].
Hemlibra® [emicizumab], RoActemra® preparations [tocilizumab], Truvada®[emtricitabine with tenofovir disoproxil], Yervoy® [ipilimumab].
For further details on changes in the BNFC click on changes.